Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
20.06. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.06. | BioAtla reports promising trial results for cancer drug | 4 | Investing.com | ||
16.05. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
BIOATLA Aktie jetzt für 0€ handeln | |||||
07.05. | BioAtla stock holds $1 target, JMP affirms Market Outperform | 2 | Investing.com | ||
06.05. | BioAtla files to sell 9.68M shares of common stock for holders | 3 | Seeking Alpha | ||
06.05. | BioAtla, Inc. - 10-Q, Quarterly Report | 6 | SEC Filings | ||
06.05. | BioAtla, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
05.05. | A Preview Of BioAtla's Earnings | 3 | Benzinga.com | ||
24.04. | BioAtla, Inc.: BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting | 2 | GlobeNewswire (USA) | ||
23.04. | BioAtla, Inc.: BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | 2 | GlobeNewswire (USA) | ||
21.04. | BioAtla stock holds $1 target, Market Outperform rating | 3 | Investing.com | ||
31.03. | BioAtla stock price target cut to $1 by Citizens JMP | 2 | Investing.com | ||
28.03. | BioAtla stock price target cut to $10 at BTIG, retains Buy rating | 4 | Investing.com | ||
28.03. | BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody | 1 | FierceBiotech | ||
27.03. | BioAtla announces 30% workforce reduction | 3 | Seeking Alpha | ||
27.03. | BioAtla, Inc.: BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress | 194 | GlobeNewswire (Europe) | CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing... ► Artikel lesen | |
27.03. | BioAtla, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
26.03. | Earnings Outlook For BioAtla | 4 | Benzinga.com | ||
20.03. | BioAtla, Inc.: BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings | 2 | GlobeNewswire (USA) | ||
19.03. | BioAtla, Inc.: BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025 | 1 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
BB BIOTECH | 32,500 | +0,46 % | Zwischen Aufbruch und Wandel: Biotech im Check: Wo liegen die Chancen? - BB Biotech: Diversifizierung innerhalb einer Aktie | Steht die Biotech-Branche vor einem strukturellen Wandel? Enormes Innovationspotenzial und gute Voraussetzungen für M&A-Aktivitäten könnten Schwung in den Sektor bringen. Wie geht es eigentlich der... ► Artikel lesen | |
CUREVAC | 4,560 | -0,91 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,120 | -1,64 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
BIOXXMED | 0,480 | +17,07 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,840 | +1,10 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
OCUGEN | 0,858 | -1,06 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
INFLARX | 0,696 | -0,43 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 8,366 | +2,50 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
BIO-GATE | 0,880 | -10,66 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,470 | +2,17 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
VAXART | 0,433 | +2,90 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
BURCON NUTRASCIENCE | 2,635 | +1,54 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2025 Results and Reviews Operations | Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen |